Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03485976 · ClinicalTrials.gov registry record · Phase 2
Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
A Phase 2 study of Pityriasis Rubra Pilaris, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03485976 is a Phase 2 study of Pityriasis Rubra Pilaris that has completed, run by Oregon Health and Science University. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03485976, a Phase 2 study of Pityriasis Rubra Pilaris, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
15 patients with PRP will be treated with ixekizumab for 24 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit and week-24 visit. 5 visits in between these times and one follow up visit may be performed by secure videoconferencing.
Conditions Studied
Interventions
- DRUG Ixekizumab
Study Locations (1)
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-05-23 |
| Est. Completion | 2020-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03485976
The ClinicalTrials.gov registry entry for NCT03485976 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pityriasis Rubra Pilaris appearing as the primary indexed condition, and to 1 intervention - of which Ixekizumab is the first listed.
NCT03485976 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT03485976 about?
NCT03485976 is a clinical study titled "Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)". 15 patients with PRP will be treated with ixekizumab for 24 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit and week-24 visit. 5 visits in between these times and one follow up visit may be performed by secure videoconferencing.
What is the current status of trial NCT03485976?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-05-23. Estimated completion is 2020-01-13.
What conditions does trial NCT03485976 study?
This clinical trial studies the following conditions: Pityriasis Rubra Pilaris.
What interventions are being tested in trial NCT03485976?
The interventions under investigation include: Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT03485976?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03485976 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pityriasis Rubra Pilaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.